To dissect CRC molecular determinants of response to anti-PD1 agents in CRC, we compared genetic and transcriptional dysregulations between hypermutated and non-hypermutated CRCs as well as between DB- and nDB-CRCs. This evidence concerns the gene PDCD1 and colorectal carcinoma.